PRECIGEN, INC. Cost of Goods Sold (Deprecated 2018-01-31)
PRECIGEN, INC. (PGEN) reported Cost of Goods Sold (Deprecated 2018-01-31) of $10.64 million for the 3-month period ending 2018-06-30, per its 10-Q filed 2018-08-13.
Discontinued › Expense Statement › Cost of Sales
us-gaap:CostOfGoodsSold · last filed 2018-08-13
- PRECIGEN, INC. cost of goods sold (deprecated 2018-01-31) for the quarter ending 2018-06-30 was $10.64M, a 20.07% increase year-over-year.
- PRECIGEN, INC. cost of goods sold (deprecated 2018-01-31) for the quarter ending 2018-03-31 was $8.53M, a 5.29% decline year-over-year.
- PRECIGEN, INC. cost of goods sold (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $7.64M, a 7.28% decline year-over-year.
- PRECIGEN, INC. cost of goods sold (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $8.00M, a 12.61% decline year-over-year.
- PRECIGEN, INC. cost of goods sold (deprecated 2018-01-31) for fiscal 2017 was $33.26M, a 11.79% decline from fiscal 2016.
- PRECIGEN, INC. cost of goods sold (deprecated 2018-01-31) for fiscal 2016 was $37.71M, a 7.45% decline from fiscal 2015.
- PRECIGEN, INC. cost of goods sold (deprecated 2018-01-31) for fiscal 2015 was $40.75M, a 269.24% increase from fiscal 2014.
- PRECIGEN, INC. cost of goods sold (deprecated 2018-01-31) for fiscal 2014 was $11.04M, a 50059.09% increase from fiscal 2013.
| Period end | Cost of Goods Sold (Deprecated 2018-01-31) 3 month | Cost of Goods Sold (Deprecated 2018-01-31) 6 month | Cost of Goods Sold (Deprecated 2018-01-31) 9 month | Cost of Goods Sold (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2018-06-30 | $10.64M 10-Q · filed 2018-08-13 | $19.17M 10-Q · filed 2018-08-13 | $26.81M derived: sum of 3 quarters · filed 2018-08-13 | $34.81M derived: sum of 4 quarters · filed 2018-08-13 |
| 2018-03-31 | $8.53M 10-Q/A · filed 2018-08-13 | $16.17M derived: sum of 2 quarters · filed 2018-08-13 | $24.17M derived: sum of 3 quarters · filed 2018-08-13 | $33.03M derived: sum of 4 quarters · filed 2018-08-13 |
| 2017-12-31 | $7.64M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $15.64M derived: sum of 2 quarters · filed 2018-03-01 | $24.50M derived: sum of 3 quarters · filed 2018-08-13 | $33.26M 10-K · filed 2018-03-01 |
| 2017-09-30 | $8.00M 10-Q · filed 2017-11-09 | $16.86M derived: sum of 2 quarters · filed 2018-08-13 | $25.63M 10-Q · filed 2017-11-09 | $34.11M derived: sum of 4 quarters · filed 2018-08-13 |
| 2017-06-30 | $8.86M 10-Q · filed 2018-08-13 | $17.62M 10-Q · filed 2018-08-13 | $26.11M derived: sum of 3 quarters · filed 2018-08-13 | $35.26M derived: sum of 4 quarters · filed 2018-08-13 |
| 2017-03-31 | $9.01M 10-Q/A · filed 2018-08-13 | $17.24M derived: sum of 2 quarters · filed 2018-08-13 | $26.40M derived: sum of 3 quarters · filed 2018-08-13 | $37.15M derived: sum of 4 quarters · filed 2018-08-13 |
| 2016-12-31 | $8.24M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $17.39M derived: sum of 2 quarters · filed 2018-03-01 | $28.15M derived: sum of 3 quarters · filed 2018-03-01 | $37.71M 10-K · filed 2018-03-01 |
| 2016-09-30 | $9.16M 10-Q · filed 2017-11-09 | $19.91M derived: sum of 2 quarters · filed 2017-11-09 | $29.47M 10-Q · filed 2017-11-09 | $38.56M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-06-30 | $10.75M 10-Q · filed 2017-08-09 | $20.32M 10-Q · filed 2017-08-09 | $29.41M derived: sum of 3 quarters · filed 2018-03-01 | $40.62M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-03-31 | $9.56M 10-Q · filed 2017-05-10 | $18.65M derived: sum of 2 quarters · filed 2018-03-01 | $29.87M derived: sum of 3 quarters · filed 2018-03-01 | $41.63M derived: sum of 4 quarters · filed 2018-03-01 |
| 2015-12-31 | $9.09M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $20.31M derived: sum of 2 quarters · filed 2018-03-01 | $32.07M derived: sum of 3 quarters · filed 2018-03-01 | $40.75M 10-K · filed 2018-03-01 |
| 2015-09-30 | $11.21M 10-Q · filed 2016-11-09 | $22.98M derived: sum of 2 quarters · filed 2016-11-09 | $31.65M 10-Q · filed 2016-11-09 | $38.38M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-06-30 | $11.76M 10-Q · filed 2016-08-09 | $20.44M 10-Q · filed 2016-08-09 | $27.16M derived: sum of 3 quarters · filed 2017-03-01 | $31.39M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-03-31 | $8.68M 10-Q · filed 2016-05-10 | $15.40M derived: sum of 2 quarters · filed 2017-03-01 | $19.62M derived: sum of 3 quarters · filed 2017-03-01 | $19.68M derived: sum of 4 quarters · filed 2017-03-01 |
| 2014-12-31 | $6.72M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $10.95M derived: sum of 2 quarters · filed 2017-03-01 | $11.00M derived: sum of 3 quarters · filed 2017-03-01 | $11.04M 10-K · filed 2017-03-01 |
| 2014-09-30 | $4.22M 10-Q · filed 2015-11-09 | $4.28M derived: sum of 2 quarters · filed 2015-11-09 | $4.31M 10-Q · filed 2015-11-09 | $4.33M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-06-30 | $53.00K 10-Q · filed 2015-08-10 | $86.00K 10-Q · filed 2015-08-10 | $108.00K derived: sum of 3 quarters · filed 2016-02-29 | $108.00K derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-03-31 | $33.00K 10-Q · filed 2015-05-11 | $55.00K derived: sum of 2 quarters · filed 2016-02-29 | $55.00K derived: sum of 3 quarters · filed 2016-02-29 | |
| 2013-12-31 | $22.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $22.00K derived: sum of 2 quarters · filed 2016-02-29 | $22.00K 10-K · filed 2016-02-29 | |
| 2013-09-30 | $0.00 10-Q · filed 2014-11-13 | $0.00 10-Q · filed 2014-11-13 | ||
| 2012-12-31 | $0.00 10-K · filed 2015-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |